JP2019504056A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504056A5
JP2019504056A5 JP2018534668A JP2018534668A JP2019504056A5 JP 2019504056 A5 JP2019504056 A5 JP 2019504056A5 JP 2018534668 A JP2018534668 A JP 2018534668A JP 2018534668 A JP2018534668 A JP 2018534668A JP 2019504056 A5 JP2019504056 A5 JP 2019504056A5
Authority
JP
Japan
Prior art keywords
formulation
polysorbate
cyclodextrin
months
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018534668A
Other languages
English (en)
Japanese (ja)
Other versions
JP7008023B2 (ja
JP2019504056A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/069046 external-priority patent/WO2017117311A1/en
Publication of JP2019504056A publication Critical patent/JP2019504056A/ja
Publication of JP2019504056A5 publication Critical patent/JP2019504056A5/ja
Priority to JP2021188331A priority Critical patent/JP2022036977A/ja
Application granted granted Critical
Publication of JP7008023B2 publication Critical patent/JP7008023B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018534668A 2015-12-30 2016-12-28 低減されたポリソルベート分解を有する製剤 Active JP7008023B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021188331A JP2022036977A (ja) 2015-12-30 2021-11-19 低減されたポリソルベート分解を有する製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562272965P 2015-12-30 2015-12-30
US62/272,965 2015-12-30
PCT/US2016/069046 WO2017117311A1 (en) 2015-12-30 2016-12-28 Formulations with reduced degradation of polysorbate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021188331A Division JP2022036977A (ja) 2015-12-30 2021-11-19 低減されたポリソルベート分解を有する製剤

Publications (3)

Publication Number Publication Date
JP2019504056A JP2019504056A (ja) 2019-02-14
JP2019504056A5 true JP2019504056A5 (cg-RX-API-DMAC10.html) 2020-02-13
JP7008023B2 JP7008023B2 (ja) 2022-01-25

Family

ID=57868354

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018534668A Active JP7008023B2 (ja) 2015-12-30 2016-12-28 低減されたポリソルベート分解を有する製剤
JP2021188331A Withdrawn JP2022036977A (ja) 2015-12-30 2021-11-19 低減されたポリソルベート分解を有する製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021188331A Withdrawn JP2022036977A (ja) 2015-12-30 2021-11-19 低減されたポリソルベート分解を有する製剤

Country Status (15)

Country Link
US (4) US10525137B2 (cg-RX-API-DMAC10.html)
EP (1) EP3397287B8 (cg-RX-API-DMAC10.html)
JP (2) JP7008023B2 (cg-RX-API-DMAC10.html)
KR (2) KR102796135B1 (cg-RX-API-DMAC10.html)
CN (2) CN108472379B (cg-RX-API-DMAC10.html)
AU (2) AU2016380988B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018010945A2 (cg-RX-API-DMAC10.html)
CA (1) CA3007419A1 (cg-RX-API-DMAC10.html)
ES (1) ES3038408T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20250951T1 (cg-RX-API-DMAC10.html)
HU (1) HUE072357T2 (cg-RX-API-DMAC10.html)
IL (2) IL299759A (cg-RX-API-DMAC10.html)
PL (1) PL3397287T3 (cg-RX-API-DMAC10.html)
SG (1) SG11201804961UA (cg-RX-API-DMAC10.html)
WO (1) WO2017117311A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
EA202192422A1 (ru) * 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
AU2020268896B2 (en) * 2019-05-03 2024-11-28 F. Hoffmann-La Roche Ag Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
US20220233631A1 (en) 2019-06-17 2022-07-28 Intas Pharmaceuticals Ltd. Stable formulation of cetrorelix
IL289219B2 (en) * 2019-06-28 2025-06-01 Genentech Inc Composition and methods for stabilizing liquid protein formulations
AU2021208515A1 (en) 2020-01-15 2022-08-04 F. Hoffmann-La Roche Ag Methods to decrease impurities from recombinant protein manufacturing processes
US20230184750A1 (en) * 2020-03-20 2023-06-15 Glaxosmithkline Intellectual Property Development Limited Method for detecting polysorbates
IL302333A (en) * 2020-10-30 2023-06-01 Genentech Inc Purification platforms for obtaining pharmaceutical preparations with a reduced hydrolytic enzyme activity rate
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
KR20240125027A (ko) 2021-12-20 2024-08-19 베링거 인겔하임 인터내셔날 게엠베하 수성 제형 중 폴리소르베이트 20의 산화 분해도를 측정하는 방법

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (cg-RX-API-DMAC10.html)
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226L (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
CA2046909A1 (en) 1989-03-21 1990-09-22 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
JP3072330B2 (ja) 1989-07-19 2000-07-31 ジ・イミューン・レスポンス・コーポレーション 自己免疫疾患および悪性疾患の治療のためのt細胞リセプターペプチド
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
JP3597239B2 (ja) * 1994-03-31 2004-12-02 ライオン株式会社 安定な点眼剤
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2225378C (en) 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
EP1386660B1 (en) 1996-08-30 2009-09-02 Upfront Chromatography A/S Isolation of immunoglobulins
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
JP2000226336A (ja) 1998-11-30 2000-08-15 Sankyo Co Ltd 免疫グロブリン製剤
AU754808B2 (en) 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CZ305123B6 (cs) 1999-10-04 2015-05-13 Novartis Vaccines And Diagnostics, Inc. Způsob výroby kapalného farmaceutického prostředku
JP2005519580A (ja) 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 非ヒト動物由来のヒト抗肺炎球菌抗体
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
WO2003002152A2 (en) 2001-06-29 2003-01-09 Maxygen Aps Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
KR100911951B1 (ko) 2001-08-23 2009-08-13 젠맵 에이/에스 인터루킨 15 (il-15)에 대하여 특이적인 인간 항체
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
DK1594434T3 (da) 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
CN1761482A (zh) 2003-01-17 2006-04-19 纽约州立大学研究基金会 与胰腺癌相关的抗原、针对它的抗体以及诊断和治疗方法
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
ME00426B (me) 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
EP1633785B1 (en) 2003-05-21 2012-11-28 Medarex, Inc. Human monoclonal antibodies against bacillusanthracis protective antigen
DE10361599A1 (de) * 2003-12-24 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Flüssigformulierung von Antikörperkonjugaten
WO2005113592A2 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
ITMI20041245A1 (it) * 2004-06-22 2004-09-22 Ibsa Inst Biochimique Sa Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
KR20080032065A (ko) 2005-06-03 2008-04-14 제넨테크, 인크. 푸코실화 수준이 조절된 항체의 생성 방법
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
CA2642577A1 (en) 2006-02-15 2007-08-23 Tika Lakemedel Ab Methods of manufacturing corticosteroid solutions
CN101553504A (zh) 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
CA2682406A1 (en) 2007-04-02 2008-10-09 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
BRPI0916072A2 (pt) 2008-11-17 2015-11-10 Genentech Inc "uso de uma formulação, formulação farmacêutica, usos de um anticorpo 2h7 humanizado, método, método para aumentar a biodisponibilidade de um anticorpo e método de diálise in vitro"
CN101757611A (zh) * 2008-12-23 2010-06-30 天津瑞普生物技术股份有限公司 一种鸡用γ-干扰素干粉吸入剂及其制备方法
US20120294866A1 (en) * 2010-01-19 2012-11-22 F. Hoffmann-La Roche Ag Pharmaceutical formulation for proteins
PT2377830T (pt) 2010-04-16 2016-07-18 Ivoclar Vivadent Ag Vidro cerâmico de silicato de lítio e vidro de silicato de lítio, contendo óxido de metal de transição
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
KR20160105535A (ko) * 2012-03-07 2016-09-06 카딜라 핼쓰캐어 리미티드 TNF-α 항체의 약제학적 제형
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
AU2014229282B2 (en) * 2013-03-15 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Low concentration antibody formulations
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate

Similar Documents

Publication Publication Date Title
JP2021155453A5 (cg-RX-API-DMAC10.html)
JP2019512540A5 (cg-RX-API-DMAC10.html)
HRP20250951T1 (hr) Formulacije sa smanjenom razgradnjom polisorbata
HRP20192348T1 (hr) Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil eter beta-ciklodekstrina
Kim et al. Mutational approaches to improve the biophysical properties of human single-domain antibodies
US12350340B2 (en) Viscosity reduction of highly concentrated protein formulations
HRP20192285T1 (hr) Anti-ox40 protutijela i postupci uporabe
JP2016515511A5 (cg-RX-API-DMAC10.html)
JP2016513710A5 (cg-RX-API-DMAC10.html)
JP2013515071A5 (cg-RX-API-DMAC10.html)
JP2016509009A5 (cg-RX-API-DMAC10.html)
JP2016525139A5 (cg-RX-API-DMAC10.html)
JP2008520551A5 (cg-RX-API-DMAC10.html)
NZ730821A (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
HRP20120903T1 (hr) Tekuä†a formulacija koja sadrži visoku koncentraciju protutijela
CA2579861A1 (en) Formulation of pertuzumab in a histidine-acetate buffer
HRP20230733T1 (hr) Farmaceutska formulacija koja sadrži antitijela, ciklodekstrin i metionin
HRP20230210T1 (hr) Pripravci i postupci upotrebe 2-(4-klorofenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il)metil)-2,2-difluoroacetamida
ECSP21043639A (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
JP2017514868A5 (cg-RX-API-DMAC10.html)
HRP20210141T1 (hr) Ligandi koji pojačavaju bioaktivnost gonadotropina
Araki et al. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer
WO2015198257A1 (en) Stable carfilzomib injection
JP2023182736A (ja) ヒト抗il-33モノクローナル抗体含有医薬用組成物
CN114599394A (zh) 用于在低蛋白浓度下使蛋白损失最小化的组合物和方法